Mark R. Grzesiak, RPAC

Mark Grzesiak practices at Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York.

Mark Grzesiak's NPI, 1376717272, was assigned on April 22, 2008. Mark Grzesiak holds New York license 010785.

Mark Grzesiak's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center, at 450 Lakeville Rd, Lake Success, NY 11042. The practice phone is (516) 734-8281.

Mark Grzesiak's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York. Mark Grzesiak is also affiliated with Long Island Jewish Medical Center. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Mark Grzesiak to 2 more medical groups, 1 clinical lab and 1 group practice or clinic, each named with a free account. Mark Grzesiak's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Grzesiak practices, 4 sites in all. Vendor and product names are available with a free account.

Physician assistant is Mark Grzesiak's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Mark Grzesiak is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Mark Grzesiak is licensed in New York.

CMS data shows 31 Medicare services from Mark Grzesiak across 1 procedure code in 2024, all of them office visits, for 28 Medicare patients. Medicare paid $2,909 for them. Every service was in an office.

CMS counts 28 Medicare patients who saw Mark Grzesiak in 2024. The largest group is 65 to 74, with 14 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mark Grzesiak's median patient age at 69, with 52% women.

In 2024, Mark Grzesiak wrote 912 Medicare Part D claims for 266 patients. 78% of them were for generic drugs. CMS names the drug for 684 of them, across 22 drugs with 11 or more claims each, at $441,478 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Mark Grzesiak for performance year 2024, reported as part of a group. Mark Grzesiak accepts Medicare assignment, so Medicare's approved amount is taken as full payment.